Jervell and Lange-Nielsen Syndrome

Jervell and Lange-Nielsen Syndrome

Overview

Jervell and Lange-Nielsen Syndrome is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Jervell and Lange-Nielsen syndrome (JLNS) is a rare autosomal recessive genetic disorder characterized by the combination of congenital sensorineural hearing loss and a prolonged QT interval on electrocardiogram, which predisposes affected individuals to potentially life-threatening cardiac arrhythmias, including torsades de pointes and sudden cardiac death[@jervell1957]. It is one of the most severe forms of inherited long QT syndrome and represents a significant cause of sudden death in children[@schwartz2006].

Epidemiology

Jervell and Lange-Nielsen syndrome is extremely rare, with an estimated prevalence of approximately 1 in 200,000 to 1 in 500,000 live births worldwide[@neyroud1997]. The syndrome accounts for approximately 1-3% of all cases of congenital long QT syndrome and about 0.5% of congenital deafness cases[@tyson1997]. Both males and females are equally affected, and the condition has been reported in individuals of various ethnic backgrounds, though founder mutations have been identified in certain populations[@bhuiyan2008].

Genetics

Jervell and Lange-Nielsen Syndrome

Overview

Jervell and Lange-Nielsen Syndrome is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Jervell and Lange-Nielsen syndrome (JLNS) is a rare autosomal recessive genetic disorder characterized by the combination of congenital sensorineural hearing loss and a prolonged QT interval on electrocardiogram, which predisposes affected individuals to potentially life-threatening cardiac arrhythmias, including torsades de pointes and sudden cardiac death[@jervell1957]. It is one of the most severe forms of inherited long QT syndrome and represents a significant cause of sudden death in children[@schwartz2006].

Epidemiology

Jervell and Lange-Nielsen syndrome is extremely rare, with an estimated prevalence of approximately 1 in 200,000 to 1 in 500,000 live births worldwide[@neyroud1997]. The syndrome accounts for approximately 1-3% of all cases of congenital long QT syndrome and about 0.5% of congenital deafness cases[@tyson1997]. Both males and females are equally affected, and the condition has been reported in individuals of various ethnic backgrounds, though founder mutations have been identified in certain populations[@bhuiyan2008].

Genetics

Jervell and Lange-Nielsen syndrome is caused by homozygous or compound heterozygous mutations in either the KCNQ1 gene (also known as JLNS1, accounting for approximately 90% of cases) or the KCNE1 gene (JLNS2, accounting for approximately 10% of cases)[@chiang2000].

| Gene | Locus | Protein | Function |
|------|-------|---------|----------|
| KCNQ1 (JLNS1) | 11p15.5 | Kv7.1 potassium channel | Alpha subunit of the cardiac and inner ear potassium channel |
| KCNE1 (JLNS2) | 21q22.12 | MinK protein | Beta subunit that modulates Kv7.1 channel function |

These genes encode components of the I_Ks potassium channel, which is critical for cardiac repolarization and for potassium recycling in the inner ear[@sanguinetti1996]. Loss-of-function mutations lead to both cardiac electrical abnormalities (prolonged QT interval) and cochlear dysfunction (sensorineural hearing loss)[@barhanin1996].

Pathophysiology

Cardiac Pathology

The prolonged QT interval results from impaired cardiac repolarization due to reduced I_Ks potassium current. The Kv7.1 channel, formed by four KCNQ1 alpha subunits辅 by KCNE1 beta subunits, is essential for the delayed rectifier potassium current that terminates the cardiac action potential[@kass2003].

In JLNS, the defective channels fail to function properly, leading to:

• Prolonged ventricular repolarization (long QT)
• Increased dispersion of repolarization
• Increased susceptibility to torsades de pointes ventricular tachycardia
• Risk of ventricular fibrillation and sudden cardiac death[@roden2006]

Inner Ear Pathology

In the cochlea, the same I_Ks channel is essential for potassium recycling during sound transduction. The strial marginal cells secrete potassium into the endolymph, and proper potassium homeostasis is critical for hair cell function. Mutations in KCNQ1 or KCNE1 disrupt this process, leading to degeneration of the outer hair cells and resulting in sensorineural hearing loss, typically profound from birth[@neyroud2001].

Clinical Features

Cardiac Manifestations

• Prolonged QT interval (typically >500 ms)
• Syncope (often triggered by emotional stress, exercise, or loud sounds)
• Seizures (due to cerebral hypoperfusion during arrhythmias)
• Cardiac arrest and sudden cardiac death (may be the first presentation)
• Torsades de pointes ventricular tachycardia
• Atrial arrhythmias

Auditory Manifestations

• Profound bilateral sensorineural hearing loss present from birth
• Typically non-progressive
• Affects all frequencies
• No vestibular symptoms (distinguishes from some other syndromic hearing losses)

Other Features

• Normal intelligence and development (unless syncope has caused cerebral injury)
• No other systemic manifestations in isolated JLNS

Diagnosis

Clinical Diagnosis

The diagnosis of JLNS is based on[@priori2013]:

Electrocardiographic Findings

• Prolonged QT interval (QTc typically >500 ms, may exceed 600 ms)
• Normal or low-normal heart rate
• T wave abnormalities
• May show characteristic notched T waves in some leads

Genetic Testing

Molecular genetic testing for KCNQ1 and KCNE1 genes confirms the diagnosis and is recommended for all patients with JLNS. Genetic testing allows for[@ackerman2011]:

• Confirmation of diagnosis
• Family screening and cascade testing
• Prognostic information (certain mutations associated with higher risk)
• Reproductive counseling

Differential Diagnosis

• Romano-Ward syndrome: Autosomal dominant long QT syndrome WITHOUT hearing loss (mutations in same genes but heterozygous)
• Other forms of congenital long QT syndrome (LQT1-LQT16)
• Isolated congenital sensorineural hearing loss (non-syndromic)
• Other syndromic causes of hearing loss with cardiac involvement

Management

Cardiac Management

The primary goal of management is to prevent sudden cardiac death[@moss2000]:

• Avoid competitive sports and strenuous exercise
• Avoid loud noises and sudden auditory stimuli
• Avoid QT-prolonging medications
• Maintain adequate hydration and electrolyte balance
• Prompt treatment of infections and fever

Hearing Management

• Cochlear implants: The preferred treatment for profound deafness. Early implantation (before age 1-2) is associated with better auditory outcomes and supports speech and language development.
• Hearing aids: May provide limited benefit for some individuals with residual hearing.
• Sign language and visual communication: Early intervention with sign language and visual supports.
• Assistive listening devices: FM systems and other assistive technologies.
• Educational support: Specialized educational services for deaf children.

Surveillance

• Regular cardiac follow-up: ECG and clinical evaluation every 6-12 months, more frequent during growth periods
• Holter monitoring: Periodic 24-hour ECG monitoring to assess arrhythmia burden
• Audiological monitoring: Regular hearing assessments, though hearing loss is typically non-progressive
• Eye examinations: Recommended to rule out associated visual problems[@garson1993]

Prognosis

Without appropriate treatment, Jervell and Lange-Nielsen syndrome carries a very high risk of sudden cardiac death, with approximately 50% of affected individuals experiencing a cardiac event (syncope, seizure, cardiac arrest, or sudden death) by age 15 years[@horner2010].

With modern management including beta-blockers, lifestyle modifications, and when needed ICD therapy, the prognosis has improved significantly. However, JLNS remains a high-risk condition requiring lifelong surveillance and strict adherence to therapy.

Early diagnosis is critical — identification of affected infants through newborn hearing screening followed by cardiac evaluation can allow for early intervention and prevention of sudden death[@vincent2017].

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

Recent research on Jervell and Lange-Nielsen Syndrome includes:

• 2024: [Title](https://pubmed.ncbi.nlm.nih.gov/XXXXX/) - Description

References